{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0"},{"groupId":"OG001","value":"67.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"description":"PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as \\>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.","groups":[{"description":"Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m\\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.","id":"OG001","title":"Lapatinib + Capecitabine"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants on the basis of the treatment assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)","title":"Percentage of Participants With PD or Death as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}